Aliaksei Salei MD, Presenter: Nothing to Disclose

Aparna Srinivasa Babu MD, Abstract Co-Author: Nothing to Disclose

Oleg Teytelboym MD, Abstract Co-Author: Nothing to Disclose

Become familiar with National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer management Understand impact of Gleason score and PSA level on diagnostic algorithm and detection of bone metastases Understand accuracy, imaging pitfalls, and optimal use of available modalities for detection of bone metastasis: CT, MRI, PET-CT, ProstaScint and Tc-99m MDP scans Become familiar with radiopharmaceuticals used for bone metastases treatment Identify challenges in follow up and treatment response evaluation in metastatic disease to the bone

Overview of epidemiology and clinical implications of bone metastases Review of NCCN algorithm for newly diagnosed prostate cancer: Biopsy and staging PSA and Gleason score Risk stratification and indications for metastatic work up Pictorial illustration of metastatic workup with standard and emerging modalities: CT and MRI PET-CT: FDG, 18F-NaC, C-11 Acetate Nuclear Medicine: Tc-99m MDP, ProstaScint Illustration of imaging pitfalls ("superscan", flare phenomenon, etc) and practical tips for improving diagnostic accuracy Review of treatment options for bone metastases with emphasis on radiopharmaceuticals (Radium-223, Samarium-153) Review challenges such as bone metastases treatment response assessment

http://abstract.rsna.org/uploads/2014/14006184/14006184_jnv7.pdf

Salei, A, Srinivasa Babu, A, Teytelboym, O, Bone Metastases in Prostate Cancer: From Diagnosis to Treatment.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14006184.html